Results 141 to 150 of about 117,919 (266)

Is Obesity a Major Driver of Primary Aldosteronism? [PDF]

JACC Basic Transl Sci
Hall JE, Omoto ACM, Hall ME.
europepmc   +1 more source

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral‐treated human immunodeficiency virus infection

Internal Medicine Journal, EarlyView.
Abstract Background and Aims Antiretroviral therapy (ART) has modified the incidence of renal complications and the patterns of renal disease in people living with Human Immunodeficiency Virus (PLWH). We reviewed (2011–2021) the progress and outcomes (follow‐up to mid‐2025) of 158 such individuals.
Jacqueline A. Evans, Christopher S. B. Sia, Gopal Basu, Orla O’Brien, Alan H. Pham, Rowan G. Walker   +5 more
wiley   +1 more source

Improving primary aldosteronism diagnosis and treatment: outcomes from an endocrine hypertension service

Internal Medicine Journal, EarlyView.
Abstract Aims To evaluate the sustained impact of the Endocrine Hypertension Service on primary aldosteronism (PA) diagnosis and management over a subsequent 3‐year period. Background PA is a prevalent yet underdiagnosed cause of secondary hypertension, associated with increased cardiovascular, renal and metabolic risk. Limited awareness, resources and
Minn W. Chow, Chrislyn Ng, Jimmy Shen, Peter J. Fuller, Jun Yang, Renata Libianto   +5 more
wiley   +1 more source

At the heart of home‐based care: multidisciplinary heart failure management in a quaternary centre's community programmes

Internal Medicine Journal, EarlyView.
Abstract Background Heart failure (HF) is a frequent cause of hospital admissions, carrying a high risk of hospital readmission and mortality. Alfred Health General Medicine Hospital in the Home (GM‐HITH) and Hospital Admission Risk Program (HARP) offer multidisciplinary HF care to multimorbid patients in bed‐substitution and non‐admitted community ...
Elana Forbes, Ingrid Hopper, Cathy Corbett, Felice Borghmans, Emma O'Donnell, Ana Slavnic, Genevieve Harvey, Elizabeth Rochford, Archana Thayaparan   +8 more
wiley   +1 more source

Rare coexistence of aldosterone resistance and adrenal insufficiency in asymptomatic infant with persistent hyperkalaemia: A case report. [PDF]

World J Clin Pediatr
Wan-Nik FH, Zulkeflee HA, Ab Rahim NS, Tuan-Ismail ST.   +3 more
europepmc   +1 more source

Early Bleeding Risk After DOAC Initiation With Concomitant Amiodarone in Older Adults With Atrial Fibrillation

Journal of Cardiovascular Electrophysiology, EarlyView.
ABSTRACT Background Amiodarone is frequently co‐prescribed with direct oral anticoagulants (DOACs) in atrial fibrillation (AF), but its impact on early bleeding risk after DOAC initiation in older adults remains uncertain. We evaluated short‐term safety outcomes associated with concomitant amiodarone use at the time of DOAC initiation.
Isadora D. Guarino, Saman Nazarian
wiley   +1 more source

Is It Time to Retire Aldosterone Suppression Testing? [PDF]

Am J Hypertens
Kline GA, Leung AA, Orton D, MacFarlane J, Gurnell M.   +4 more
europepmc   +1 more source

Liraglutide combined with dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice

Journal of Diabetes Investigation, EarlyView.
Liraglutide combined with Dapagliflozin treatment improves myocardial disease and endothelial dysfunction in T2DM mice. Diabetic cardiomyopathy (DCM) and endothelial dysfunction were established in mice via HFD and STZ injection. The combination therapy of Liraglutide and Dapagliflozin synergistically improved metabolic parameters and attenuated ...
An‐Jun Tan, Tian‐Rong Li, Jing‐Jing Yang, Xiao‐Lu Li, Wen‐Qin Li, Jin‐Wen Yu   +5 more
wiley   +1 more source

The Importance of Plasma Renin Concentrations in Intensive Care Patients with Circulatory Shock. [PDF]

J Clin Med
Bozkurt Turan Y, Karakurt S.
europepmc   +1 more source

Developing a machine learning model to predict renal function decline within three years using one‐year longitudinal data in patients with type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
We developed a machine learning model to predict renal function decline in patients with type 2 diabetes and preserved kidney function. Using one year of routine clinical data, the model forecasts eGFR decline over three years, enabling early identification of high‐risk patients and supporting timely, targeted therapeutic interventions.
Mari Kaneda, Shu Meguro, Kaiken Kimura, Youichiro Harada, Makoto Enomoto, Kaori Hayashi   +5 more
wiley   +1 more source